Comparative Pharmacology
Head-to-head clinical analysis: CYMBALTA versus MILNACIPRAN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYMBALTA versus MILNACIPRAN HYDROCHLORIDE.
CYMBALTA vs MILNACIPRAN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin and norepinephrine reuptake inhibitor (SNRI); increases extracellular levels of serotonin and norepinephrine by inhibiting their reuptake into presynaptic neurons.
Milnacipran is a serotonin-norepinephrine reuptake inhibitor (SNRI) with approximately 3-fold higher potency for norepinephrine reuptake inhibition compared to serotonin. It does not significantly affect dopamine or other neurotransmitter reuptake.
60 mg orally once daily, without regard to meals; some patients may benefit from a starting dose of 30 mg once daily for 1 week before increasing to 60 mg once daily.
50 mg orally twice daily with food, increased to 100 mg twice daily based on tolerability and efficacy.
None Documented
None Documented
Terminal elimination half-life is approximately 12 hours (range 8–17 hours); supports once-daily dosing with consistent drug levels.
Terminal elimination half-life is approximately 6-8 hours in young adults; prolonged to 10-15 hours in elderly or patients with renal impairment (CrCl <30 mL/min).
Renal: approximately 70% as metabolites (duloxetine glucuronide conjugates and sulfate conjugates), 20% as unchanged drug in urine; fecal: approximately 20% as metabolites; biliary: minor contribution.
Primarily renal: ~60% excreted unchanged in urine; ~23% as glucuronide conjugates; ~3% as other metabolites; biliary/fecal excretion accounts for <5%.
Category C
Category C
SNRI Antidepressant
SNRI Antidepressant